Sugi Predict

Sugi Predict / Compounds / SCHEMBL1241218

SCHEMBL1241218

SCHEMBL1241218

Cn1c(=O)[nH]c(=O)c2[nH]c(Br)nc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.49
▸ GAA P10253 5/20 0.47
▸ MAPK1 P28482 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.46
▸ GLA P06280 1/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ CASP7 P55210 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ CHRNB2 P17787 1/20 0.45
▸ ADRA1D P25100 1/20 0.45
▸ HTR1E P28566 1/20 0.45
▸ CHRNA3 P32297 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL387339 0.79 ALDH1A1 (0.54) ALDH1A1GAAMAPK1MAPTKMT2A
SCHEMBL12233275 0.79 ADORA2A (0.55) ALDH1A1MAPTKMT2ASMN1; SMN2GLA
SCHEMBL18343921 0.78 ALDH1A1 (0.49) ALDH1A1GAAMAPK1MAPTKMT2A
SCHEMBL3563144 0.78 ALDH1A1 (0.49) ALDH1A1GAAMAPK1MAPTKMT2A
SCHEMBL10309249 0.78 ALDH1A1 (0.49) ALDH1A1GAAMAPK1MAPTKMT2A
SCHEMBL6890038 0.78 CHRNB2 (0.53) ALDH1A1GAAMAPK1MAPTKMT2A
SCHEMBL10309259 0.75 ALDH1A1 (0.61) ALDH1A1GAAMAPK1MAPTKMT2A
SCHEMBL10309247 0.75 GAA (0.65) ALDH1A1GAAMAPK1MAPTKMT2A
SCHEMBL16870007 0.74 CHRNB2 (0.57) ALDH1A1GAAMAPK1MAPTKMT2A
Pamabrom SCHEMBL237881 0.74 POLB (0.61) ALDH1A1MAPK1KMT2ASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638452-A1 PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE Boehringer Ingelheim International GmbH (DE) 2025-10-29 — — EP claimed
EP-4560315-A2 HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES F. Hoffmann-La Roche AG (CH) 2025-05-28 — — EP claimed
EP-3980554-B1 HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES HOFFMANN LA ROCHE (CH) 2025-03-26 — — EP claimed
WO-2024133476-A1 PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-27 — — WO claimed
US-20240208976-A1 PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-27 — — US claimed
CN-112379018-B Method for detecting 3-methylxanthine in linagliptin starting material A 济南立德医药技术有限公司 2022-07-19 — — CN claimed
US-20220195497-A1 HYBRIDIZING all-LNA OLIGONUCLEOTIDES ROCHE DIAGNOSTICS OPERATIONS, INC. 2022-06-23 — — US claimed
EP-3980554-A1 HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES F. Hoffmann-La Roche AG (CH) 2022-04-13 — — EP claimed
CN-113939599-A Hybrid all-LNA oligonucleotides 豪夫迈·罗氏有限公司 2022-01-14 — — CN claimed
CN-109705122-B Preparation method of linagliptin intermediate for treating type II diabetes 深圳市第二人民医院 2021-11-16 — — CN claimed
CN-112724140-A Novel preparation process of linagliptin 山东永丞制药有限公司 2021-04-30 — — CN claimed
CN-112209929-A Novel preparation process of linagliptin 山东永丞制药有限公司 2021-01-12 — — CN claimed
WO-2020245377-A1 HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES F. HOFFMANN-LA ROCHE AG (CH) 2020-12-10 — — WO claimed
CN-111285876-A Linagliptin intermediate isomer impurity, preparation method and application thereof 重庆圣华曦药业股份有限公司 2020-06-16 — — CN claimed
CN-105936634-A Synthetic method of linagliptin 赤峰赛林泰药业有限公司 2016-09-14 — — CN claimed
CN-105503872-A Linagliptin impurity, and preparation method and application thereof BEIJING PUDEKANGLI PHARMACEUTICAL TECH DEV CO LTD 2016-04-20 — — CN claimed
US-20260117148-A1 SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE FUJIFILM CORP (JP) 2026-04-30 — — US disclosed
EP-4661847-A1 PHARMACEUTICAL COMPOSITION COMPRISING 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE Boehringer Ingelheim International GmbH (DE) 2025-12-17 — — EP disclosed
WO-2002002560-A2 PURINE-2,6-DIONES WHICH ARE INHIBITORS OF THE ENZYME DIPEPTIDYL PEPTIDASE IV (DPP-IV) NOVO NORDISK A/S (DK) 2002-01-10 — — WO disclosed
WO-2000061583-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117148-A1 SEMICONDUCTOR TREATMENT LIQUID, TREATMENT METHOD FOR OBJECT TO BE TREATED, AND MANUFACTURING METHOD OF ELECTRONIC DEVICE TPMT, P2RY13, TST ALDH1A1 2119/4885GAA 1300/4885MAPK1 2265/4885
US-20240208976-A1 PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE DPYD, P2RX7, DHPS ALDH1A1 497/4885GAA 2177/4885MAPK1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.